Skip to main content
SpringerLink
Log in

Thromboseprophylaxe und -therapie bei Tumorpatienten

Richtiges Vorgehen in Krankenhaus und Praxis

  • CME • TOPIC • thromboseprophylaxe und -therapie
  • Published:
best practice onkologie Aims and scope

Zusammenfassung

Häufig werden Tumorerkrankungen primär oder in ihrem Verlauf durch venöse Thrombosen und/oder Lungenembolien kompliziert. Dies bedeutet für die betroffenen Patienten ein erhöhtes Mortalitätsrisiko: Venöse Thromboembolien wurden in Untersuchungen als zweithäufigste zum Tode der Patienten führende Komplikation identifiziert. Der Beitrag gibt einen Überblick zur Prophylaxe und Behandlung von venösen Thromboembolien bei Tumorpatienten.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Agnelli G, Gussoni G, Bianchini C et al (2008) A randomized doubleblind placebocontrolled study on nadroparin for prophylaxis of thromboembolic events in cancer patients receiving chemotherapy: The PROTECHT Study. Blood 112: 6 (abstr)

    Google Scholar 

  2. Bottaro FJ, Elizondo MC, Doti C et al (2008) Efficacy of extended thromboprophylaxis in major abdominal surgery: What does the evidence show? A metaanalysis. Thromb Haemost 99: 1104–1111

    CAS  PubMed  Google Scholar 

  3. Chaukiyal P, Nautiyal A, Radhakrishnan S et al (2008) Thromboprophylaxis in cancer patients with central venous catheters: A systematic review and metaanalysis. Thromb Haemost 99: 38–43

    CAS  PubMed  Google Scholar 

  4. Falanga A, Marchetti M (2009) Venous Thromboembolism in the Hematologic Malignancies. J Clin Oncol 27: 4848–4857

    Article  CAS  PubMed  Google Scholar 

  5. Geerts WH, Bergqvist D, Pineo GF et al (2008) Prevention of venous thromboembolism: American College of Chest Physicians EvidenceBased Clinical Practice Guidelines (ed 8). Chest 133: 381S–453S

    Article  CAS  PubMed  Google Scholar 

  6. Herishanu Y, Misgav M, Kirgner I et al (2004) Enoxaparin can be used safely in patients with severe thrombocytopenia due to intensive chemotherapy regimens. Leuk Lymphoma 45: 1407–1411

    Article  CAS  PubMed  Google Scholar 

  7. Kearon C, Kahn SR, Agnelli G et al (2008) Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidencebased clinical practice guidelines (ed 8). Chest 133: 454S–545S

    Article  CAS  PubMed  Google Scholar 

  8. Klerk CP, Smorenburg SM, Otten HM et al (2005) The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23: 2130–2135

    Article  CAS  PubMed  Google Scholar 

  9. Khorana AA, Kuderer NM, Culakova E et al (2008) Development and validation of a predictive model for chemotherapyassociated thrombosis. Blood 111: 4902–4907

    Article  CAS  PubMed  Google Scholar 

  10. Kuderer NM, Khorana AA, Lyman GH et al (2007) A metaanalysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: Impact on survival and bleeding complications. Cancer 110: 1149–1161

    Article  CAS  PubMed  Google Scholar 

  11. Lee AY, Levine MN, Baker RI et al (2003) Lowmolecularweight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349: 146–153

    Article  CAS  PubMed  Google Scholar 

  12. Prandoni P, Falanga A, Piccioli A (2005) Cancer and venous thromboembolism. Lancet Oncol 6: 401–410

    Article  PubMed  Google Scholar 

  13. Riess H, Pelzer U, Deutschinoff G et al (2009) A prospective randomized trial of chemotherapy with and without the low molecular heparin enoxaparin in patients with advanced pancreatic cancer: Results of the CONKO 004 trial. J Clin Oncol 27: 798s (abstr.)

    Google Scholar 

  14. Sorensen HT, Hohnsen SP (2008) Venous thromboembolism and subsequent shortterm risk of an occult cancer. J Thromb Haemost 6: 249–250

    CAS  PubMed  Google Scholar 

  15. Zangari M, Fink LM, Elice F et al (2009) Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol 27: 4865–4873

    Article  CAS  PubMed  Google Scholar 

  16. Cortes C, Saura C, Atzori F (2009) risk of venous thromboembolism with Bevacizumab in cancer patients. JAMA 301:1434–1435

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitätsmedzin Berlin, Charité Campus Virchow Klinikum, Medizinische Klinik mit Schwerpunkt, Hämatologie und Onkologie, CharitéCentrum für Tumormedizin, Charité Comprehensive Cancer Center, Berlin, Germany

    H. Riess

  2. Universitätsmedizin Berlin, Charité Campus Virchow Klinikum, CharitéCentrum für Tumormedizin, Charité Comprehensive Cancer Center, Augustenburger Platz 1, 13353, Berlin, Germany

    H. Riess

Authors
  1. H. Riess
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Riess.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Riess, H. Thromboseprophylaxe und -therapie bei Tumorpatienten. best practice onkologie 5, 44–52 (2010). https://doi.org/10.1007/s11654-009-0207-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11654-009-0207-3

Search

Navigation